Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss

Am J Kidney Dis. 2008 Feb;51(2):298-301. doi: 10.1053/j.ajkd.2007.10.039.


Imatinib mesylate (Gleevec, Glivec; Novartis, Basel, Switzerland) is a specific tyrosine kinase inhibitor that has become the gold-standard treatment for patients with chronic myeloid leukemia. Several tyrosine kinases inhibited by imatinib are expressed in the kidney, and although the drug is usually well tolerated, several cases of acute renal failure were reported. We describe for the first time a case of a patient treated by imatinib for chronic myeloid leukemia who developed partial Fanconi syndrome with mild renal failure, which leads to a discussion of the pathophysiological characteristics of imatinib-induced renal toxicity. Patients on long-term imatinib treatment should be monitored for renal failure, as well as proximal tubule dysfunction, including hypophosphatemia.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Benzamides
  • Fanconi Syndrome / chemically induced*
  • Fanconi Syndrome / physiopathology
  • Fanconi Syndrome / urine
  • Female
  • Humans
  • Hypophosphatemia / chemically induced*
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Middle Aged
  • Phosphates / urine*
  • Piperazines / administration & dosage
  • Piperazines / adverse effects*
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects*


  • Antineoplastic Agents
  • Benzamides
  • Phosphates
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases